Table 1 Demographic and clinical characteristics of the patients by group
Variables | SLE group (n = 68) | Control group (n = 50) | p-value |
|---|---|---|---|
Age, years | 45.50 (12.67) | 52.76 (14.45) | 0.003 |
Female sex, n (%) | 58 (85.3) | 43 (86) | 0.914* |
Body mass index, kg/m2 | 24.64 (3.91) | 25.79 (3.73) | 0.070 |
BCVA, logMAR | 0.010 (0.051) | 0.005 (0.020) | 0.890 |
IOP-Goldmann, mm Hg | 13.60 (2.88) | 13.76 (2.55) | 0.738 |
Spherical equivalent, D | − 0.25 (− 1.0 to 0.25) | 0.13 (− 0.63 to 1.0) | 0.048 |
Axial length, mm | 23.56 (1.00) | 22.89 (0.96) | < 0.001 |
MAP, mm Hg | 88.71 (11.06) | 91.92 (13.11) | 0.114 |
SLE duration, years | 11.0 (6.25–19.0) | NA | |
SLEDAI | 2 (0–4) | NA | |
HCQ | |||
Daily dose, mg | 329 (96) | NA | |
Cumulative dose, g | 778 (228.1–1606.0) | NA | |
Therapy duration, years | 5.30 (1.81–11.83) | NA | |
Daily dose/weight, mg/kg | 5.02 (1.61) | NA | |
Cumulative dose/weight, g/kg | 10.76 (3.16–25.47) | NA | |
NP-SLE, n (%) | 19 (27.9) | NA | |
Central NP-SLE, n (%) | 16 (23.5) | NA | |
Peripheral NP-SLE, n (%) | 3 (4.4) | NA | |
Lupus nephritis, n (%) | 18 (26.5) | NA | |
Antiphospholipid syndrome, n (%) | 21 (30.9) | NA | |
Sjogren’s syndrome, n (%) | 5 (7.4) | NA | |